Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Agrees With Industry: PET Coverage Process Should Be Overhauled

This article was originally published in The Gray Sheet

Executive Summary

Medical imaging equipment manufacturers should play a more active role in the development of Medicare coverage policies for diagnostic imaging technologies, CMS Coverage & Analysis Director Steve Phurrough said May 7 at an AdvaMed meeting on Medicare policy in Baltimore

You may also be interested in...



Call For More PET Tech Assessment Studies To Shape CMS Coverage Debate

Preliminary evidence bodes well for positron emission tomography (PET) to be used as an adjunct in initially diagnosing cervical, ovarian, pancreatic, small-cell lung and testicular cancers, but further confirmatory studies are needed, according to AHRQ

Call For More PET Tech Assessment Studies To Shape CMS Coverage Debate

Preliminary evidence bodes well for positron emission tomography (PET) to be used as an adjunct in initially diagnosing cervical, ovarian, pancreatic, small-cell lung and testicular cancers, but further confirmatory studies are needed, according to AHRQ

Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS

CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel